At Acadia, our mission is to turn scientific promise into meaningful innovation that makes the difference for underserved neurological disorders and rare disease communities around the world. Currently, our clinical-stage developments focus on addressing Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with early-stage programs that address other unmet patient needs. We are working to seek approval of our treatment option for people living with Rett syndrome in Europe.
Acadia submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for its proposed treatment option for Rett syndrome in the European Union. On 26 June 2026, Acadia announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation in the EU. Read the press release (PDF).
Our Focus
Our clinical-stage development efforts are focused on Alzheimer’s disease psychosis and multiple other programmes targeting neuropsychiatric symptoms in central nervous system disorders.
